Synopsis

Source of validity: Scientific
Rating (out of 5): 4

Immunoglobulin G (IgG) has a well-established role in the prevention of hepatitis A and hepatitis B, particularly in pre-exposure and post-exposure prophylaxis. The use of immunoglobulin preparations to prevent hepatitis A dates back to the 1940s, with modern preparations containing high titers of anti-hepatitis A antibodies. Scientific studies have demonstrated that intramuscular administration of IgG is effective in providing temporary, passive immunity against hepatitis A virus (HAV) infection, significantly reducing the risk of clinical hepatitis when administered before or shortly after exposure. Similarly, hepatitis B immune globulin (HBIG), a specific IgG preparation, is used alongside hepatitis B vaccination to prevent hepatitis B virus (HBV) infection, especially in newborns of infected mothers or individuals with recent exposure to HBV. This approach is backed by robust clinical evidence and international guidelines. However, it is important to note that IgG is not used to treat established hepatitis infections; its use is limited to prevention and post-exposure prophylaxis. For chronic hepatitis or active infection, antiviral therapies are the mainstay. In summary, the application of IgG in the context of hepatitis is scientifically validated, but limited to specific, prophylactic scenarios rather than treatment of active disease.

More about Immunoglobulin G
More about Hepatitis

Other ingredients used for Hepatitis

Other health conditions supported by Immunoglobulin G

Products containing Immunoglobulin G